Radiation therapy dose escalation for glioblastoma multiforme in the era of temozolomide

International Journal of Radiation Oncology Biology Physics

Volumn 90, Issue 4, 2014, Pages 877-885

  Badiyan, Shahed N ^a   Markovina, Stephanie ^a   Simpson, Joseph R ^a   Robinson, Clifford G ^a   DeWees, Todd ^a   Tran, David D ^a   Linette, Gerry ^a   Jalalizadeh, Rohan ^a   Dacey, Ralph ^a   Rich, Keith M ^a   Chicoine, Michael R ^a   Dowling, Joshua L ^a   Leuthardt, Eric C ^a   Zipfel, Gregory J ^a   Kim, Albert H ^a   Huang, Jiayi ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MULTIVARIANT ANALYSIS;

CLINICAL OUTCOME; GLIOBLASTOMA MULTIFORME; KARNOFSKY PERFORMANCE STATUS; METHODS AND MATERIALS; MULTI VARIATE ANALYSIS; NEWLY DIAGNOSED GLIOBLASTOMA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL;

RADIOTHERAPY;

TEMOZOLOMIDE; ALKYLATING AGENT; DACARBAZINE;

ADULT; AGE; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; HUMAN; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE ESCALATION; RADIATION DOSE FRACTIONATION; TREATMENT OUTCOME; AGED; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; COMPUTER ASSISTED RADIOTHERAPY; DISEASE FREE SURVIVAL; FOLLOW UP; MAINTENANCE CHEMOTHERAPY; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PROCEDURES; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DACARBAZINE; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84908174745     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2014.07.014     Document Type: Article

References (34)

1. Q.T. Ostrom, H. Gittleman, and P. Farah CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010 Neuro Oncol 15 Suppl. 2 2013 ii1 56
2. R. Stupp, W.P. Mason, and M.J. van den Bent Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 2005 987 996
3. M.D. Walker, S.B. Green, and D.P. Byar Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery N Engl J Med 303 1980 1323 1329
4. K. Kristiansen, S. Hagen, and T. Kollevold Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: A prospective multicenter trial of the Scandinavian Glioblastoma Study Group Cancer 47 1981 649 652
5. M.D. Walker, E. Alexander Jr., and W.E. Hunt Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial J Neurosurg 49 1978 333 343
6. M.D. Walker, T.A. Strike, and G.E. Sheline An analysis of dose-effect relationship in the radiotherapy of malignant gliomas Int J Radiat Oncol Biol Phys 5 1979 1725 1731
7. N.M. Bleehen, and S.P. Stenning A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party Br J Cancer 64 1991 769 774
8. C.H. Chang, J. Horton, and D. Schoenfeld Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study Cancer 52 1983 997 1007
9. N.J. Laperriere, P.M. Leung, and S. McKenzie Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma Int J Radiat Oncol Biol Phys 41 1998 1005 1011
10. L. Souhami, W. Seiferheld, and D. Brachman Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: Report of Radiation Therapy Oncology Group 93-05 protocol Int J Radiat Oncol Biol Phys 60 2004 853 860
11. R.G. Selker, W.R. Shapiro, and P. Burger The Brain Tumor Cooperative Group NIH Trial 87-01: A randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine Neurosurgery 51 2002 343 355 discussion 355-357
12. J.L. Chan, S.W. Lee, and B.A. Fraass Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy J Clin Oncol 20 2002 1635 1642
13. A.M. Monjazeb, D. Ayala, and C. Jensen A phase I dose escalation study of hypofractionated IMRT field-in-field boost for newly diagnosed glioblastoma multiforme Int J Radiat Oncol Biol Phys 82 2012 743 748
14. C.B. Scott, W.J. Curran, and W.K. Yung Long term results of RTOG 9006: A randomized trial of hyperfractioanted radiotherapy (RT) to 72.0 Gy and carmustine vs. standard RT and carmustine for malignant glioma patients with emphasis on anaplastic astrocytoma patients (Abstr.) Proc Am Soc Clin Oncol 17 1998 401
15. M.E. Hegi, A.C. Diserens, and T. Gorlia MGMT gene silencing and benefit from temozolomide in glioblastoma N Engl J Med 352 2005 997 1003
16. C. Nieder, and M.P. Mehta Advances in translational research provide a rationale for clinical re-evaluation of high-dose radiotherapy for glioblastoma Med Hypotheses 76 2011 410 413
17. M. Ammirati, S. Chotai, and H. Newton Hypofractionated intensity modulated radiotherapy with temozolomide in newly diagnosed glioblastoma multiforme J Clin Neurosci 21 2014 633 637
18. N. Jastaniyah, A. Murtha, and N. Pervez Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme Radiat Oncol 8 2013 38
19. M. Massaccesi, M. Ferro, and S. Cilla Accelerated intensity-modulated radiotherapy plus temozolomide in patients with glioblastoma: A phase I dose-escalation study (ISIDE-BT-1) Int J Clin Oncol 18 2013 784 791
20. K. Reddy, D. Damek, and L.E. Gaspar Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme Int J Radiat Oncol Biol Phys 84 2012 655 660
21. C.I. Tsien, D. Brown, and D. Normolle Concurrent temozolomide and dose-escalated intensity-modulated radiation therapy in newly diagnosed glioblastoma Clin Cancer Res 18 2012 273 279
22. S.M. Yoon, J.H. Kim, and S.J. Kim Hypofractionated intensity-modulated radiotherapy using simultaneous integrated boost technique with concurrent and adjuvant temozolomide for glioblastoma Tumori 99 2013 480 487
23. T. Iuchi, K. Hatano, and T. Kodama Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma Int J Radiat Oncol Biol Phys 88 2014 793 800
24. X.S. Qi, C.J. Schultz, and X.A. Li An estimation of radiobiologic parameters from clinical outcomes for radiation treatment planning of brain tumor Int J Radiat Oncol Biol Phys 64 2006 1570 1580
25. J.N. Mandrekar, S.J. Mandrekar, and S.S. Cha Cutpoint determination methods in survival analysis using SAS® [Conference Proceedings] SUGI 28 2003 261 268 Available at http://www2.sas.com/proceedings/sugi28/261-28.pdf. Accessed August 13, 2014
26. N.F. Marko, R.J. Weil, J.L. Schroeder, F.F. Lang, D. Suki, and R.E. Sawaya Extent of resection of glioblastoma revisited: Personalized survival modeling facilitates more accurate survival prediction and supports a maximum-safe-resection approach to surgery J Clin Oncol 32 2014 774 782
27. N.S. Chaudhry, A.H. Shah, and N. Ferraro Predictors of long-term survival in patients with glioblastoma multiforme: Advancements from the last quarter century Cancer Invest 31 2013 287 308
28. E.C. Halperin, G. Bentel, and E.R. Heinz Radiation therapy treatment planning in supratentorial glioblastoma multiforme: An analysis based on post mortem topographic anatomy with CT correlations Int J Radiat Oncol Biol Phys 17 1989 1347 1350
29. R.G. Verhaak, K.A. Hoadley, and E. Purdom Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1 Cancer Cell 17 2010 98 110
30. R. Stupp, M.E. Hegi, and W.P. Mason Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial Lancet Oncol 10 2009 459 466
31. Y. Liu, S. Shete, and C.J. Etzel Polymorphisms of LIG4, BTBD2, HMGA2, and RTEL1 genes involved in the double-strand break repair pathway predict glioblastoma survival J Clin Oncol 28 2010 2467 2474
32. A. Chakravarti, A. Chakladar, and M.A. Delaney The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner Cancer Res 62 2002 4307 4315
33. M.A. Chaudhry, H. Sachdeva, and R.A. Omaruddin Radiation-induced micro-RNA modulation in glioblastoma cells differing in DNA-repair pathways DNA Cell Biol 29 2010 553 561
34. S. Bao, Q. Wu, and R.E. McLendon Glioma stem cells promote radioresistance by preferential activation of the DNA damage response Nature 444 2006 756 760